Professor Michael Tatley

2023

Conference Contribution - Published proceedings: Abstract

Savage, R., Lee, J., & Tatley, M. (2023). Impact of general practice on medicine and vaccine safety in New Zealand. Australian Journal of General Practice, (Suppl. 2), (pp. 238). Retrieved from https://www1.racgp.org.au/ajgp/home

2022

Journal - Research Article

Ameratunga, R., Woon, S.-T., Sheppard, M. N., Garland, J., Ondruschka, B., Wong, C. X., … Tatley, M., … Tse, R. D. (2022). First identified case of fatal fulminant necrotizing eosinophilic myocarditis following the initial dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): An extremely rare idiosyncratic hypersensitivity reaction. Journal of Clinical Immunology, 42, 441-447. doi: 10.1007/s10875-021-01187-0

2021

Journal - Research Article

Robson, H., Braund, R., Glass, M., Ashton, J., & Tatley, M. (2021). Synthetic cannabis: Adverse events reported to the New Zealand Pharmacovigilance Centre. Clinical Toxicology, 59(6), 472-479. doi: 10.1080/15563650.2020.1828592

Journal - Research Other

Bennett, M., Chang, C. L., Tatley, M., Savage, R., & Hancox, R. J. (2021). The safety of cardio-selective beta1-blockers in asthma: Literature review and search of global pharmacovigilance safety reports. ERJ Open Research, 7, 1-10. doi: 10.1183/23120541.00801-2020

2019

Journal - Research Other

Savage, R. L., Hill, G. R., Barnes, J., Kenyon, S. H., & Tatley, M. V. (2019). Suspected hepatotoxicity with a supercritical carbon dioxide extract of Artemisia annua in grapeseed oil used in New Zealand [Brief research report article]. Frontiers in Pharmacology, 10, 1448. doi: 10.3389/fphar.2019.01448

Conference Contribution - Published proceedings: Abstract

Chan, L., Kenyon, S., & Tatley, M. (2019). Using spontaneous reports to confirm the safety profile of vaccines. Proceedings of the 5th Pharmacoepidemiology Research Network Symposium. Retrieved from https://www.otago.ac.nz/pharmacoepidemiology

2018

Journal - Research Other

Savage, R. L., & Tatley, M. V. (2018). Case series analysis of New Zealand reports of rapid intense potentiation of warfarin by roxithromycin [Short communcation]. Drug Safety, 41(5), 515-521. doi: 10.1007/s40264-017-0634-y

Conference Contribution - Published proceedings: Abstract

Storey, M., Savage, R., Stenlund, J., Tatley, M., & Kenyon, S. (2018). Using the M² scheme to investigate safety signals. Proceedings of the 4th Pharmacoepidemiology Research Network Symposium. (pp. 12). Retrieved from https://www.otago.ac.nz/pharmacoepidemiology

Tatley, M. (2018). Strengthening pharmacovigilance and medicines support systems in the Pacific. Proceedings of the Pacific International Health Symposium. (pp. 16). Retrieved from https://pihs.squarespace.com

Savage, R. L., Tatley, M., & Barnes, J. (2018). Hepatotoxicity with a natural dietary supplement, Artemisia annua L. extract in grapeseed oil. New Zealand Pharmacovigilance Centre Reports. Drug Safety, 41(11), (pp. 1151). doi: 10.1007/s40264-018-0719-2

Braund, R., & Tatley, M. (2018). Adverse drug reaction reports following a "brand switch". The New Zealand experience. Drug Safety, 41(11), (pp. 1193-1194). doi: 10.1007/s40264-018-0719-2

2017

Journal - Research Other

Savage, R. L., Castellano, M., & Tatley, M. V. (2017). International reports of unexpected low plasma concentrations of dabigatran suggest that more frequent measurements will add value. Seminars in Thrombosis & Hemostasis, 43(6), 635-638. doi: 10.1055/s-0037-1603361

Conference Contribution - Published proceedings: Abstract

Savage, R., & Tatley, M. (2017). Rapid onset of very high INR values when roxithromycin prescribed with warfarin challenges the accepted mechanism. Drug Safety, 40(10), (pp. 963-964). doi: 10.1007/s40264-017-0580-8

Conference Contribution - Verbal presentation and other Conference outputs

Savage, R., Tatley, M., & Kunac, D. (2017, July). Fifty years of adverse drug reaction reporting in New Zealand: Primary care involvement and the developing use of e-health. Verbal presentation at the Royal New Zealand College of General Practitioners (RNZCGP) Conference for General Practice Quality Symposium, Dunedin, New Zealand.

2016

Conference Contribution - Published proceedings: Abstract

Tatley, M., Savage, R., Kunac, D., & Ashton, J. (2016). Years of pharmacovigilance in New Zealand: Lessons in sustainability and growth. Drug Safety, 39(10), (pp. 1001). doi: 10.1007/s40264-016-0445-6

Savage, R., Clark, P., & Tatley, M. (2016). Taking a fresh look at identifying and responding to drug-induced illness. Proceedings of the Royal New Zealand College of General Practitioners (RNZCGP) Conference for General Practice. Retrieved from http://www.generalpractice.org.nz/gp16

2015

Conference Contribution - Published proceedings: Abstract

Savage, R., & Tatley, M. (2015). Comparison of New Zealand and international spontaneous reports of adverse reactions occurring within one week of zoledronic acid infusion with the information in New Zealand product data sheets. In J. Young (Ed.), Proceedings of the Annual General Practice and Primary Care Research Weekend. (pp. 27-28). Dunedin, New Zealand: Department of General Practice and Rural Health, University of Otago. [Abstract]

Conference Contribution - Verbal presentation and other Conference outputs

Skegg, D., Sharples, K., Barson, D., Edwards, R., & Tatley, M. (2015, November). What do the next 5(0) years hold? Panel discussion at the Inaugural Pharmacoepidemiology Research Network Symposium, Dunedin, New Zealand.

2014

Chapter in Book - Research

Harrison-Woolrych, M., Tatley, M., & Kunac, D. (2014). Pharmacovigilance in New Zealand. In E. B. Andrews & N. Moore (Eds.), Mann's pharmacovigilance. (3rd ed.) (pp. 291-294). Chichester, UK: Wiley Blackwell. doi: 10.1002/9781118820186.ch16a

Journal - Research Article

Kunac, D. L., Tatley, M. V., & Seddon, M. E. (2014). A new web-based Medication Error Reporting Programme (MERP) to supplement pharmacovigilance in New Zealand: Findings from a pilot study in primary care. New Zealand Medical Journal, 127(1401). Retrieved from http://www.nzma.org.nz/journal

2013

Journal - Research Article

Holst, J., Oster, P., Arnold, R., Tatley, M. V., Næss, L. M., Aaberge, I. S., … Black, S. (2013). Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future. Human Vaccines & Immunotherapeutics, 9(6), 1241-1253. doi: 10.4161/hv.24129

2012

Journal - Research Other

Kunac, D., Tatley, M. V., Grimwood, K., & Reith, D. M. (2012). Active surveillance of serious adverse drug reactions in New Zealand children. Archives of Disease in Childhood, 97(8), 761-762. doi: 10.1136/archdischild-2011-301457

2011

Journal - Research Article

Kunac, D. L., & Tatley, M. V. (2011). Detecting medication errors in the New Zealand Pharmacovigilance Database: A retrospective analysis. Drug Safety, 34(1), 59-71. doi: 10.2165/11539290-000000000-00000

Conference Contribution - Published proceedings: Abstract

Tatley, M. (2011). AEFI reports to CARM: The credible, the causal and the unusual. Proceedings of the 7th New Zealand National Immunisation Conference and Workshop. Retrieved from http://www.immune.org.nz/health-professionals/imac-conference-and-workshops

Tatley, M. (2011). AEFI: A New Zealand population level perspective. Proceedings of the 7th New Zealand National Immunisation Conference and Workshop. Retrieved from http://www.immune.org.nz/health-professionals/imac-conference-and-workshops

Tatley, M. (2011). Dabigatran preventable events? [Share and Learn Series]. Proceedings of the International Medication Safety Network (IMSN) Annual Meeting. Retrieved from http://www.intmedsafe.net/contents/pastmeeting.aspx

Conference Contribution - Poster Presentation (not in published proceedings)

Kunac, D., & Tatley, M. (2011, October-November). Preventability assessment of adverse drug reaction (ADR) reports: Taking the 'p-method' to the next level. Poster session presented at the Thirty-Fourth Representatives of National Centres Participating in the WHO Programme for International Drug Monitoring Annual Meeting, Dubrovnik, Croatia.

Conference Contribution - Verbal presentation and other Conference outputs

Tatley, M. (2011, October-November). Dabigatran related cardiac failure? Verbal presentation at the 34th Annual Meeting of Representatives of the National Centres Participating in the WHO Programme for International Drug Monitoring: Problems of Current Interest, Dubrovnik, Croatia.

2010

Conference Contribution - Verbal presentation and other Conference outputs

Tatley, M. (2010, September). Monitoring New Zealand's Vaccine Safety. Verbal presentation at the Immunisation National Workshop for Health Professionals, Auckland, New Zealand.

Tatley, M. (2010, September). Improving patient safety through medication error surveillance. Verbal presentation at the New Zealand General Practitioners Conference Research Day: Doing the Right Thing, Christchurch, New Zealand.

2009

Journal - Research Other

Tatley, M. (2009). Monitoring of generic medicines and brand changes. Best Practice Journal, (July), 18-20.

Conference Contribution - Published proceedings: Abstract

James, C. M., Tatley, M., Savage, R., Kenyon, S. H., & Jessamine, S. (2009). Eltroxin formulation change: The New Zealand experience. Drug Safety, 32(10), (pp. 900). [Abstract]

2008

Journal - Research Article

Kunac, D. L., Harrison-Woolrych, M., & Tatley, M. V. (2008). Pharmacovigilance in New Zealand: The role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use. New Zealand Medical Journal, 121(1283). Retrieved from http://journal.nzma.org.nz/journal/121-1283/3286/content.pdf

Tatley, M. V., Kunac, D. L., McNicholas, A., Zhou, L., Ballantyne, S., Ashton, J., … Reid, S. (2008). The Intensive Vaccines Monitoring Programme (IVMP): An electronic system to monitor vaccine safety in New Zealand. Vaccine, 26(22), 2746-2752. doi: 10.1016/j.vaccine.2008.03.017

2007

Journal - Research Article

McNicholas, A., Galloway, Y., Stehr-Green, P., Reid, S., Radke, S., Sexton, K., … Tatley, M., … O'Hallahan, J. (2007). Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Human Vaccines, 3(5), 196-204.

Tatley, M., & Savage, R. (2007). Psychiatric adverse reactions with statins, fibrates and ezetimibe: Implications for the use of lipid-lowering agents. Drug Safety, 30(3), 195-201.

Journal - Research Other

Barnes, J., & Tatley, M. (2007). Scant reporting on CAMs safety in NZ. Pharmacy Today, (February), 6.

Conference Contribution - Published proceedings: Abstract

Savage, R. L., & Tatley, M. (2007). Pancreatitis with serious sequelae in patients taking ezetimibe. Drug Safety, 30(10). [Abstract]

2006

Authored Book - Research

Ministry of Health, including Chambers, S., Jennings, L., & Tatley, M. (2006). Immunisation Handbook 2006. Wellington, New Zealand: Ministry of Health, 455p.

Journal - Professional & Other Non-Research Articles

Tatley, M. (2006). Adverse events reported with the MeNZB. New Zealand Doctor, (November), 19.

Conference Contribution - Published proceedings: Abstract

Tatley, M. V. (2006). Vaccine safety monitoring of the MeNZB™ vaccine using electronic data transfer and assessment. Drug Safety. 29(10), (pp. 1004). [Abstract]

Savage, R. L., & Tatley, M. (2006). Method for developing an adverse reaction profile for a medicine using national and international spontaneous reports. Drug Safety. 29(10), (pp. 964). [Abstract]

Conference Contribution - Verbal presentation and other Conference outputs

Tatley, M. (2006, October). Cardiac failure with omeprazole. Verbal presentation at the Twenty-ninth Annual Meeting of Representatives of the National Centres Participating in the WHO Programme for International Drug Monitoring, Liège, Belgium.

Commissioned Report for External Body

Centre for Adverse Reactions Monitoring, including Tatley, M. (2006). Summary of Centre for Adverse Reactions Monitoring reports of MeNZB™ adverse events. Commissioned by Meningococcal Vaccine Strategy Independent Safety Monitoring Board. Dunedin, New Zealand: Centre for Adverse Reaction Monitoring.

2004

Journal - Research Other

Savage, R., & Tatley, M. (2004). Myopathy with statins: Check CK levels and interactions. Prescriber Update, 25(1), 4-5. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

2002

Journal - Research Article

Tatley, M. V. (2002). The monitoring of adverse events following immunisation. New Zealand Medical Journal, 115(1165).

Journal - Research Other

Tatley, M. (2002). Pulmonary reactions with nitrofurantoin. Prescriber Update, 23(2), 24-25. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

2001

Journal - Research Other

Tatley, M. (2001). Ticlopidine, Clopidogrel and Thrombotic Thrombocytopenic Purpura. Prescriber Update, 20, 19-21. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Tatley, M. (2001). Your guide to adverse reaction reporting. Prescriber Update, 22, 21-25. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Tatley, M. (2001). Bupropion (Zyban^TM) for second-line treatment only. Prescriber Update, 22, 4-8. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

2000

Journal - Research Other

Zwarenstein, M., Shoeman, J. H., Vundule, C., Lombard, C. J., & Tatley, M. V. (2000). A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis. International Journal of Tuberculosis & Lung Disease, 4(6), 550-554.

1998

Journal - Research Article

Zwarenstein, M., Schoeman, J. H., Vandule, C., Lombard, C. J., & Tatley, M. (1998). Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet, 352(9137), 1340-1343.